A global, pivotal Phase 3 clinical trial of BLU-285 in third line patients with KIT-driven GIST

Trial Profile

A global, pivotal Phase 3 clinical trial of BLU-285 in third line patients with KIT-driven GIST

Planning
Phase of Trial: Phase III

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs BLU 285 (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 07 Aug 2017 New trial record
    • 02 Aug 2017 According to a Blueprint Medicines media release, the company is planning to initiate this trial in the first half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top